Search

Your search keyword '"Magheli, Ahmed"' showing total 394 results
Start Over Author "Magheli, Ahmed"
394 results on '"Magheli, Ahmed"'

1. Urologische Tumoren

Author

Mohnike, Wolfgang, Magheli, Ahmed, Lampe, Matthias, Fink, Christoph A., Schmitt, Dominik, Niegisch, Günter, Körber, Stefan, Mohnike, Wolfgang, editor, Mohnike, Konrad, editor, and Lampe, Matthias, editor

Published
2024
Full Text
View/download PDF

3. Diagnostic Utility of Artificial Intelligence–assisted Transperineal Biopsy Planning in Prostate Cancer Suspected Men: A Prospective Cohort Study

Author

Guenzel, Karsten, primary, Lukas Baumgaertner, Georg, additional, Padhani, Anwar R., additional, Luckau, Johannes, additional, Carsten Lock, Uwe, additional, Ozimek, Tomasz, additional, Heinrich, Stefan, additional, Schlegel, Jakob, additional, Busch, Jonas, additional, Magheli, Ahmed, additional, Struck, Julian, additional, Borgmann, Hendrik, additional, Penzkofer, Tobias, additional, Hamm, Bernd, additional, Hinz, Stefan, additional, and Alexander Hamm, Charlie, additional

Published
2024
Full Text
View/download PDF

6. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results

Author

Motzer, Robert J, Ravaud, Alain, Patard, Jean-Jacques, Pandha, Hardev S, George, Daniel J, Patel, Anup, Chang, Yen-Hwa, Escudier, Bernard, Donskov, Frede, Magheli, Ahmed, Carteni, Giacomo, Laguerre, Brigitte, Tomczak, Piotr, Breza, Jan, Gerletti, Paola, Lechuga, Mariajose, Lin, Xun, Casey, Michelle, Serfass, Lucile, Pantuck, Allan J, and Staehler, Michael

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Kidney Disease, Clinical Trials and Supportive Activities, Clinical Research, Cancer, Genetics, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Aged, Angiogenesis Inhibitors, Carcinoma, Renal Cell, Chemotherapy, Adjuvant, Disease-Free Survival, Female, Humans, Indoles, Kaplan-Meier Estimate, Kidney Neoplasms, Male, Middle Aged, Nephrectomy, Proportional Hazards Models, Pyrroles, Risk Factors, Sunitinib, Time Factors, Treatment Outcome, Adjuvant, Disease-free survival, Renal cell carcinoma, Urology & Nephrology, Clinical sciences
Abstract

BackgroundAdjuvant sunitinib significantly improved disease-free survival (DFS) versus placebo in patients with locoregional renal cell carcinoma (RCC) at high risk of recurrence after nephrectomy (hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.59-0.98; p=0.03).ObjectiveTo report the relationship between baseline factors and DFS, pattern of recurrence, and updated overall survival (OS).Design, setting, and participantsData for 615 patients randomized to sunitinib (n=309) or placebo (n=306) in the S-TRAC trial.Outcome measurements and statistical analysisSubgroup DFS analyses by baseline risk factors were conducted using a Cox proportional hazards model. Baseline risk factors included: modified University of California Los Angeles integrated staging system criteria, age, gender, Eastern Cooperative Oncology Group performance status (ECOG PS), weight, neutrophil-to-lymphocyte ratio (NLR), and Fuhrman grade.Results and limitationsOf 615 patients, 97 and 122 in the sunitinib and placebo arms developed metastatic disease, with the most common sites of distant recurrence being lung (40 and 49), lymph node (21 and 26), and liver (11 and 14), respectively. A benefit of adjuvant sunitinib over placebo was observed across subgroups, including: higher risk (T3, no or undetermined nodal involvement, Fuhrman grade ≥2, ECOG PS ≥1, T4 and/or nodal involvement; hazard ratio [HR] 0.74, 95% confidence interval [CI] 0.55-0.99; p=0.04), NLR ≤3 (HR 0.72, 95% CI 0.54-0.95; p=0.02), and Fuhrman grade 3/4 (HR 0.73, 95% CI 0.55-0.98; p=0.04). All subgroup analyses were exploratory, and no adjustments for multiplicity were made. Median OS was not reached in either arm (HR 0.92, 95% CI 0.66-1.28; p=0.6); 67 and 74 patients died in the sunitinib and placebo arms, respectively.ConclusionsA benefit of adjuvant sunitinib over placebo was observed across subgroups. The results are consistent with the primary analysis, which showed a benefit for adjuvant sunitinib in patients at high risk of recurrent RCC after nephrectomy.Patient summaryMost subgroups of patients at high risk of recurrent renal cell carcinoma after nephrectomy experienced a clinical benefit with adjuvant sunitinib.Trial registrationClinicalTrials.gov NCT00375674.

Published
2018

9. Supplementary Figure S1 from Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib

Author

Rini, Brian I., primary, Escudier, Bernard, primary, Martini, Jean-Francois, primary, Magheli, Ahmed, primary, Svedman, Christer, primary, Lopatin, Margarita, primary, Knezevic, Dejan, primary, Goddard, Audrey D., primary, Febbo, Phillip G., primary, Li, Rachel, primary, Lin, Xun, primary, Valota, Olga, primary, Staehler, Michael, primary, Motzer, Robert J., primary, and Ravaud, Alain, primary

Published
2023
Full Text
View/download PDF

11. Supplementary Table S1 from Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib

Author

Rini, Brian I., primary, Escudier, Bernard, primary, Martini, Jean-Francois, primary, Magheli, Ahmed, primary, Svedman, Christer, primary, Lopatin, Margarita, primary, Knezevic, Dejan, primary, Goddard, Audrey D., primary, Febbo, Phillip G., primary, Li, Rachel, primary, Lin, Xun, primary, Valota, Olga, primary, Staehler, Michael, primary, Motzer, Robert J., primary, and Ravaud, Alain, primary

Published
2023
Full Text
View/download PDF

12. Table S2 from Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis

Author

George, Daniel J., primary, Martini, Jean-Francois, primary, Staehler, Michael, primary, Motzer, Robert J., primary, Magheli, Ahmed, primary, Donskov, Frede, primary, Escudier, Bernard, primary, Li, Sherry, primary, Casey, Michelle, primary, Valota, Olga, primary, Laguerre, Brigitte, primary, Pantuck, Allan J., primary, Pandha, Hardev S., primary, Patel, Anup, primary, Lechuga, Maria, primary, and Ravaud, Alain, primary

Published
2023
Full Text
View/download PDF

29. Robot-Assisted versus Laparoscopic Donor Nephrectomy: A Comparison of 250 Cases

Author

Zeuschner, Philip, Hennig, Linda, Peters, Robert, Saar, Matthias, Linxweiler, Johannes, Siemer, Stefan, Magheli, Ahmed, Kramer, Jürgen, Liefeldt, Lutz, Budde, Klemens, Schlomm, Thorsten, Stöckle, Michael, Friedersdorff, Frank, and Augustin, Matthias

Subjects
robot-assisted surgery, organ donation, kidney transplantation, minimally-invasive donor nephrectomy, laparoscopic surgery, living kidney donation
Published
2021
Full Text
View/download PDF

46. Illness representations, coping and anxiety among men with localized prostate cancer over an 18‐months period: A parallel vs. level‐contrast mediation approach.

Author

Otto, Isabella, Hilger, Caren, Magheli, Ahmed, Stadler, Gertraud, and Kendel, Friederike

Subjects
PROSTATE cancer patients, PSYCHOLOGICAL adaptation, ANXIETY, SENSE of coherence, PSYCHOLOGICAL distress, WATCHFUL waiting
Abstract

Objective: Men diagnosed with localized prostate cancer (lPCa) are confronted with the decision for a treatment strategy, potentially experiencing treatment side effects and psychological distress. The Common Sense Model proposes that coping with such challenges is related to illness representations: Beliefs regarding consequences, coherence, timeline, and controllability of the illness. We analyzed the interplay of illness representations, coping and anxiety over an 18‐month period among men with lPCa undergoing different treatment options (Active Surveillance, curative treatment). Methods: In this longitudinal study, 183 men (age M = 66.83) answered a questionnaire before starting treatment, and 6, 12, and 18 months later. We analyzed time trajectories with growth curve modeling and conducted mediation analyses to evaluate the influence of coping on the association of illness representations and anxiety. Using a novel methodological approach, we compared a classic parallel mediation model with a level‐contrast approach for the correlated mediators problem‐ and emotion‐focused coping. Results: Independent of treatment (b = 1.31, p = 0.200) men reported an elevated level of anxiety after diagnosis which declined considerably within the following 6 months (b = −1.87, p = 0.009). The perceived seriousness of consequences was significantly associated with greater anxiety, at baseline (β = 0.471) and over time (all β ≥ 0.204). This association was mediated by coping: Using more emotion‐than problem‐focused coping was associated with higher anxiety. Conclusions: Receiving a lPCa diagnosis is associated with a phase of increased anxiety. In order to reduce anxiety, information provision should be accompanied by developing concrete action plans to enable problem‐focused coping strategies. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

50. Peri- und postoperatives Ergebnis nach Nierentumorchirurgie bei pT1/pT2-Nierenzellkarzinom – eine retrospektive Zentrumsanalyse der funktionellen und onkologischen Ergebnisse

Author

Ralla, Bernhard, additional, Buhl, Stephanie, additional, Goranova, Irena, additional, Maxeiner, Andreas, additional, Friedersdorff, Frank, additional, Magheli, Ahmed, additional, Hinz, Stefan, additional, Fuller, Florian T., additional, Miller, Kurt, additional, and Busch, Jonas, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results